77.9%
Tempus AIadvanced solid malignancyBASECAMP-1logic-gated Tmod chimeric antigen receptor T-cell therapiesBASECAMP-1A2 Biotherapeuticsadvanced solid malignancies
… status. To further optimise our approach, we co-developed with Tempus AI (Tempus) the bioinformatic programme Aware, which identifies po…